United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

Eli Lilly

Merck

We have been long-term owners of Amgen ( AMGN , Financial), Merck ( MRK , Financial) and Pfizer ( PFE , Financial) among the major pharma and biotech companies. We believe they trade at a ridiculous discount to similar companies in other industries.

Good Medicine at Bargain Prices

Oracle

These investments offer investors a good mix of value and growth.

Dump FAANG and Buy These 3 Cheaper Growth Stocks Instead

The drugmaker could lose millions of dollars, but investors don't seem to be worried.

Why Pfizer Halted Shipments of 1 of Its Top-Selling Products

Moderna

The "full" approval of Pfizer and Moderna's COVID-19 vaccines sometime this year could boost sagging vaccination rates in the U.S., though the Food and Drug Administration's decision may not happen until the end of the year.

Full FDA approval of Pfizer's and Moderna's COVID-19 shots would reinvigorate the U.S. vaccination push — but it could still be months away

BioNTech SE

The FDA on Friday added a warning to patient and provider fact sheets for the Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) COVID-19 vaccines to indicate a rare risk of heart inflammation. The fact sheets were revised for each vaccine to warn about myocarditis and pericarditis after the second dose and with the onset of symptoms within a few days after receiving the shot.

FDA Revises Pfizer, Moderna COVID-19 Vaccine Sheets With Rare Heart Inflammation Warning

Scientists found that, even four months after the first dose, the body continues to train new immune cells to protect against Covid-19, which suggests robust protection.

Pfizer And Moderna Vaccines May Offer Years-Long Protection Against Covid-19, Scientists Say

Pfizer ( PFE , Financial) is one of the largest healthcare companies in the world by market capitalization and gained significant momentum over the past year given its success on the Covid-19 vaccination front.

Pfizer: The Evergreen Pharma Blue-chip

The FDA mentions cases of heart inflammation in young people.

Could a Vaccine Warning Label Hurt Moderna and Pfizer?

Pfizer is one of the world's largest pharmaceutical companies, has an A+ credit rating, and has raised the dividend for 11 consecutive years. Pfizer's successful COVID-19 vaccine drove Q1 2021 operational earnings to a 42% growth (8% excluding the vaccine).

Dividend Sleuthing: Pfizer

The humanitarian move might help the companies gain additional for-profit contracts in the future.

Here's Why Pfizer and BioNTech Are Selling Their Vaccine at Cost

For each Covid-19 vaccine, the fact sheets were revised to include a warning about myocarditis and pericarditis after the second dose

FDA adds warning about risk of rare heart inflammation to Pfizer, Moderna Covid vaccines

Here's why some of the best-performing stocks of 2021 could have more upside ahead.

Reopening Stocks Have Soared in 2021 -- but Is All the Good News Priced In?

After finding unacceptable levels of potential carcinogens called nitrosamines in certain Chantix (varenicline) lots, Pfizer Inc (NYSE: PFE) has halted the worldwide distribution of the popular smoking cessation medicine. A spokesman said the company believes the drug's benefits "outweigh the very low potential risks, if any, posed by nitrosamine exposure from varenicline on top of other common sources over a lifetime.

Pfizer Stops Global Smoking Cessation Pill Distribution After Flagging Impurities: Report

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient has been enrolled in a randomized, controlled Phase II study evaluating the combination of TG4001 with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023). TG4001 IS AN INVESTIGATIONAL THERAPEUTIC VACCINE TARGETING HPV-PO

Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers

Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.

Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study

Pfizer commercializes one of the best COVID drugs with BioNTech, but it is not a vaccine-focused company.

Is Pfizer Stock Still A Buy In 2021? For The Right Investors, Yes

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company's common stock, payable September 7, 2021, to holders of the Common Stock of record at the close of business on July 30, 2021. The third-quarter 2021 cash dividend will be the 331st consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to b

Pfizer Declares Third-Quarter 2021 Dividend

At its current price levels (~$39), an investment in Pfizer represents a wide moat business for sale at a fair price.

Pfizer: A Wide Moat Business At A Fair Price

Shares of COVID-19 vaccine companies Moderna Inc (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) are moving sharply lower Wednesday. What Happened: Administering of mRNA vaccines, the class of vaccines developed by Moderna and Pfizer-BioNTech, resulted in higher observed vs.

Moderna, Pfizer Stocks Fall After CDC Panel Flags Heart Inflammation Risk In Young Adults Receiving COVID-19 Vaccine

Pfizer has underperformed the market so much it feels the market is actively not giving credit for its Covid-19 vaccine. While the Covid-19 vaccine is less important itself for profits, the R&D effort and the messenger RNA give the company great option value.

Serendipity, Pfizer And A Value Investment

Lawsuit tests anti-kickback law that has snared pharmaceutical giants.

Pfizer argues its case in federal court for helping seniors meet drug copays

Even as variants emerge and the war against COVID-19 is far from over, Pfizer doesn't appear to be on track to overcome some of its pre-pandemic hurdles to growth. After an expected surge in sales and profits as a result of the pandemic, the company is expected to report declining figures for the better part of the next decade.

Pfizer: Fully Vaccinated

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-se

First Participant Dosed in Pfizer's Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

AstraZeneca

CureVac B.V

Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.

How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

New research published in JAMA found there was no difference in sperm parameters in 45 men who received mRNA vaccines against COVID-19. The two authorized mRNA vaccines, which were developed by Pfizer Inc. and Moderna Inc. , are the most commonly utilized COVID-19 vaccines in the U.S. Researchers at the University of Miami Miller School of Medicine say they initiated the study after hearing concerns from some people that the vaccines could impact fertility.

News for Pfizer Stock (PFE)